SCHEMBL247351

SCHEMBL247351

CC(=O)Oc1ccccc1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.57
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57
HSD17B10 Q99714 2/20 0.57
ESR1 P03372 1/20 0.57
ITGB3 P05106 1/20 0.57
ITGA2B P08514 1/20 0.57
HMGB1 P09429 1/20 0.57
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57
GGT1 P19440 1/20 0.57
PTGS1 P23219 1/20 0.57
BLM P54132 1/20 0.57
NAPRT Q6XQN6 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
CYP4F2 P78329 1/20 0.53
CYP4A11 Q02928 1/20 0.53
LMNA P02545 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL4479016 0.98 PTGS2 (0.55) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL7690182 0.91 HSD17B10 (0.49) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL27616771 0.89 PTGS2 (0.47) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL338196 0.84 PTGS2 (0.68) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL29432883 0.84 PTGS2 (0.68) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL1700833 0.83 MAPK1 (0.49) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL31200468 0.83 MAPK1 (0.49) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL5691679 0.83 KMT2A (0.47) PTGS2ALDH1A1KDM4EHSD17B10ESR1
SCHEMBL2940941 0.82 FAAH (0.49) ALDH1A1KDM4EHPGDLMNAKMT2A
SCHEMBL18697277 0.82 FAAH (0.49) ALDH1A1KDM4EHPGDLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 356 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034297-A1 VANADIUM-BASED CATALYTIC SYSTEM INCLUDING ACTIVATOR AND METHOD FOR OLEFIN POLYMERIZATION CHANGCHUN UNIVERSITY OF TECHNOLOGY (CN) 2025-01-30 US claimed
CN-116033897-A Phenol derivatives 住友制药株式会社 2023-04-28 CN claimed
US-10483466-B2 P-doping cross-linking of organic hole transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2019-11-19 US claimed
EP-3114715-B1 P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS SIEMENS AG (DE) 2019-10-30 EP claimed
US-20180198069-A1 P-Doping Cross-Linking Of Organic Hole Transporters SIEMENS AKTIENGESELLSCHAFT (DE) 2018-07-12 US claimed
US-20130274284-A1 PREPARATION OF PRASUGREL HYDROCHLORIDE DR. REDDY'S LABORATORIES, INC. (US) 2013-10-17 US claimed
EP-2601200-A2 PREPARATION OF PRASUGREL HYDROCHLORIDE Dr. Reddy's Laboratories Ltd. (IN) 2013-06-12 EP claimed
WO-2012018791-A2 PREPARATION OF PRASUGREL HYDROCHLORIDE DR. REDDY'S LABORATORIES LTD. (IN) 2012-02-09 WO claimed
WO-2012001486-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL HYDROCHLORIDE AND ITS INTERMEDIATES MAYUKA LABS PVT. LTD. (IN) 2012-01-05 WO claimed
US-20090197167-A1 Fluorinated Additives For Lithium Ion Batteries SOLVAY FLUOR GMBH (DE) 2009-08-06 US claimed
CN-101380317-A Pharmaceutical composition for relieving pruritus CAYMAN ISLAND SHANGANSHENG DEV (CN) 2009-03-11 CN claimed
EP-1938404-A1 FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES Solvay Fluor GmbH (DE) 2008-07-02 EP claimed
WO-2007042471-A1 FLUORINATED ADDITIVES FOR LITHIUM ION BATTERIES SOLVAY FLUOR GMBH (DE) 2007-04-19 WO claimed
EP-4673138-A1 NBD1 MODULATORS AND METHODS OF USING THE SAME Sionna Therapeutics Inc. (US) 2026-01-07 EP disclosed
US-12473283-B2 Compounds and their use DEBIOPHARM INTERNATIONAL S.A. (CH) 2025-11-18 US disclosed
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-18 US disclosed
EP-0354693-A1 Therapeutic agents The Boots Company PLC (GB) 1990-02-14 EP disclosed
EP-0106565-B1 LEUKOTRIENE ANTAGONISTS, THEIR PRODUCTION, AND COMPOSITIONS CONTAINING THEM MERCK FROSST CANADA INC. (CA) 1986-09-10 EP disclosed
EP-0106565-A1 Leukotriene antagonists, their production, and compositions containing them MERCK FROSST CANADA INC. (CA) 1984-04-25 EP disclosed
US-4411974-A FOR NEGATIVE TONERS XEROX CORPORATION (US) 1983-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274284-A1 PREPARATION OF PRASUGREL HYDROCHLORIDE PFKP, PF4, PTAFR PTGS2 325/4885ALDH1A1 1209/4885KDM4E 2825/4885
US-20250287942-A1 FORMULATIONS FOR REPELLING BEES AND OTHER INSECTS ACHE, BCHE, DDT PTGS2 3674/4885ALDH1A1 4134/4885KDM4E 1597/4885
US-12473283-B2 Compounds and their use LSS, PGLS, LDHB PTGS2 2891/4885ALDH1A1 1859/4885KDM4E 111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.